标题：Clinical Evaluation of Antidyslipidemic Effect of Unani Polyherbal Formulation (Habb-e-Sundrus) - A Randomized Single Blind Standard Controlled Study
期刊名称：International Journal of Innovative Research in Science, Engineering and Technology
印刷版ISSN：2347-6710
电子版ISSN：2319-8753
出版年度：2017
卷号：6
期号：7
页码：12883
DOI：10.15680/IJIRSET.2017.0607075
出版社：S&S Publications
摘要：Background &Objective: Dyslipidemia is a major cause of atherosclerosis as it plays a pivotal role inits pathogenesis and related consequences. Deaths related to cardiovascular origin, especially from coronary heartdisease is at the top globally. There are ample evidences determined which confirmed association between dyslipidemiaand cardiovascular diseases. Hypolipidemic agents (statins) used in conventional medicine have low efficacy andproduces intolerable or life-threatening adverse effects, primarily if they are used for a longer duration. In Unani systemof medicine, the concept of Dusumat-e-Dam (lipid in blood/dyslipidemia) was lucubrated and managed extensively bysingle and compound drugs but not validated on scientific parameters. Hence, present study was designed to evaluatethe efficacy and safety of Habb-e-Sundrus (Unani polyherbal formulation) in dyslipidemia.Methods: Present study was single blinded, randomized, standard controlled clinical trial conducted at NIUM, hospitalfrom March 2015 to December 2015 on sample size of 33 subjects. After taking written informed consent subjects wererandomly allocated into two groups (22 in test group and 11 in control group). Test group was treated with powder ofHabb-e-Sundrus (5gm twice a day) and control group treated with tablet atorvastatin (10 mg once a day) orally for 45days consecutively. Subjective parameters (dyspnoea on exertion and fatigue) were assessed on each follow-ups (i.e. on0th, 15th, 30th and 45th days) while objective parameters (lipid profile and BMI) were measured at 0th day and 45th day oftrial. Results were analyzed using Student‘t’ test, Chi-square and Fisher Exact test.Results: Serum triglyceride, Very low density lipoprotein, BMI and subjective parameters were shown statisticallysignificant changes over time (45 days) in both test and control groups (p<0.05). However, intergroup analysis revealedthat differences in all investigated parameters were statistically non-significant. Safety parameters founds within thenormal range.Conclusion: It can be concluded that, use of either Habb-e-Sundrus or Atorvastatin is equally safe and effective in themanagement of dyslipidemia.
关键词：Dyslipidemia; Siman-e-Mufrit; Habb-e-Sundrus; Atorvastatin; Unani Medicine
